Kyverna Therapeutics, Inc. Additional Paid in Capital, Common Stock
Kyverna Therapeutics, Inc. (KYTX) had Additional Paid in Capital, Common Stock of $668.56 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-11
- 2026-06-30: Additional Paid in Capital, Common Stock $668.56M.
- 2026-03-31: Additional Paid in Capital, Common Stock $660.23M.
- 2025-12-31: Additional Paid in Capital, Common Stock $657.00M.
- 2025-09-30: Additional Paid in Capital, Common Stock $538.94M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $668.56M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $660.23M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $657.00M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $538.94M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $534.63M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $532.17M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $530.00M 10-K · filed 2026-03-26 |
| 2024-09-30 | $528.59M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $525.09M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $523.73M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $4.64M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |